At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 196 enrolled

Drug / intervention

lesinurad +2 moredrug

Likely dose

lesinurad 400 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01808144

NCT01808144Phase 3Completed

A Long-Term Extension Study of Lesinurad in Combination With Febuxostat for Subjects With Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat

Ardea Biosciences, Inc.·interventional·Posted Mar 11, 2013·Updated Jan 30, 2018

In Brief

A Phase 3 clinical trial evaluating lesinurad and febuxostat for Gout. Completed, enrolled 196 participants across 72 sites in 6 countries.

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsGout

CountriesAustralia, Canada, New Zealand, Poland, Switzerland, United States

Collaborators--

Phase 3CompletedFinished

20132014201520162017201820192020202120222023202420252026

Enrollment StartMar 2013

First PostedMar 2013

Primary CompletionAug 2016

Study CompletionOct 2016

TodayJul 2026

First PostedMar 11, 2013

Enrollment StartMar 1, 2013

Primary CompletionAug 9, 2016

Study CompletionOct 6, 2016

TodayJul 2, 2026

Enrollment to primary: 3.4 yearsPosted 13.3 years ago

lesinuraddrug

Tablets, 400 mg once daily (QD)

lesinuraddrug

Tablets, 200 mg QD

febuxostatdrug

Tabletsm 80 mg QD